

**Beara Pharmacy Limited**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 31 March 2025**

**Beara Pharmacy Limited**  
**CONTENTS**

	<b>Page</b>
Directors' Responsibilities Statement	3
Balance Sheet	4
Notes to the Financial Statements	5 - 8

# **Beara Pharmacy Limited**

## **DIRECTORS' RESPONSIBILITIES STATEMENT**

for the financial year ended 31 March 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### **Signed on behalf of the board**

**Edel Hickey**  
**Director**

**10 December 2025**

**Niall Cronin**  
**Director**

**10 December 2025**

# Beara Pharmacy Limited

## BALANCE SHEET

as at 31 March 2025

	Notes	2025 €	2024 €
<b>Fixed Assets</b>			
Intangible assets	6	49,500	74,000
Tangible assets	7	245,946	264,630
<b>Fixed Assets</b>		<b>295,446</b>	<b>338,630</b>
<b>Current Assets</b>			
Stocks	8	112,887	108,123
Debtors	9	160,335	148,557
Cash and cash equivalents		781,070	567,698
		<b>1,054,292</b>	<b>824,378</b>
<b>Creditors: amounts falling due within one year</b>	<b>10</b>	<b>(178,412)</b>	<b>(154,888)</b>
<b>Net Current Assets</b>		<b>875,880</b>	<b>669,490</b>
<b>Total Assets less Current Liabilities</b>		<b>1,171,326</b>	<b>1,008,120</b>
<b>Capital and Reserves</b>			
Called up share capital presented as equity		50	50
Other reserves	11	100	100
Retained earnings	11	1,171,176	1,007,970
<b>Equity attributable to owners of the company</b>		<b>1,171,326</b>	<b>1,008,120</b>

We as Directors of Beara Pharmacy Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014.

**Approved by the board on 10 December 2025 and signed on its behalf by:**

**Edel Hickey**  
Director

**Niall Cronin**  
Director

# Beara Pharmacy Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

### 1. General Information

Beara Pharmacy Limited is a company limited by shares incorporated in Ireland. Berehaven Pharmacy, Castletownbere, Co. Cork is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the year ended 31 March 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

#### Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

#### Goodwill

Purchased goodwill arising on the acquisition of a business represents the excess of the acquisition cost over the fair value of the identifiable net assets including other intangible fixed assets when they were acquired. Purchased goodwill is capitalised in the Balance Sheet and amortised on a straight line basis over its economic useful life of 20 years, which is estimated to be the period during which benefits are expected to arise. On disposal of a business any goodwill not yet amortised is included in determining the profit or loss on sale of the business.

#### Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	-	4% Straight line
Fixtures, fittings and equipment	-	12.5% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

# Beara Pharmacy Limited

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

### Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

### Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

### Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

### Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

### Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

### Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

### Ordinary share capital

The ordinary share capital of the company is presented as equity.

### 3. Going concern

The financial statements have been prepared on the assumption that the company will continue as a going concern for the foreseeable future. The directors believe that appropriate measures, strategies and plans are in place to ensure that the company will meet its ongoing requirements for at least 12 months from the date of approval of the financial statements.

The financial statements have been prepared on a going concern basis.

<b>4. Operating profit/(loss)</b>	<b>2025</b>	2024
	€	€
<b>Operating profit/(loss) is stated after charging:</b>		
Depreciation of tangible assets	<b>22,139</b>	22,085
Amortisation of goodwill	<b>24,500</b>	24,500
	<u><u>          </u></u>	<u><u>          </u></u>
<b>5. Employees</b>	<b>2025</b>	2024
	Number	Number
Directors	<b>2</b>	2
Employees	<b>12</b>	12
	<u><u>          </u></u>	<u><u>          </u></u>
	<b>14</b>	14
	<u><u>          </u></u>	<u><u>          </u></u>

**Beara Pharmacy Limited**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 31 March 2025

**6. Intangible assets**

	<b>Goodwill</b> €	<b>Total</b> €
<b>Cost</b>		
At 1 April 2024	490,000	490,000
At 31 March 2025	490,000	490,000
<b>Provision for diminution in value</b>		
At 1 April 2024	416,000	416,000
Charge for financial year	24,500	24,500
At 31 March 2025	440,500	440,500
<b>Net book value</b>		
At 31 March 2025	<b>49,500</b>	<b>49,500</b>
At 31 March 2024	74,000	74,000

**7. Tangible assets**

	<b>Land and buildings freehold</b> €	<b>Fixtures, fittings and equipment</b> €	<b>Total</b> €
<b>Cost</b>			
At 1 April 2024	239,100	142,597	381,697
Additions	-	3,455	3,455
At 31 March 2025	239,100	146,052	385,152
<b>Depreciation</b>			
At 1 April 2024	19,128	97,939	117,067
Charge for the financial year	9,564	12,575	22,139
At 31 March 2025	28,692	110,514	139,206
<b>Net book value</b>			
At 31 March 2025	<b>210,408</b>	<b>35,538</b>	<b>245,946</b>
At 31 March 2024	219,972	44,658	264,630

**8. Stocks**

	<b>2025</b> €	<b>2024</b> €
Finished goods and goods for resale	<b>112,887</b>	108,123

The replacement cost of stock did not differ significantly from the figures shown.

**9. Debtors**

	<b>2025</b> €	<b>2024</b> €
Trade debtors	<b>104,907</b>	87,574
Taxation	<b>42,637</b>	55,387
Prepayments	<b>12,791</b>	5,596
	<b>160,335</b>	148,557

## Beara Pharmacy Limited

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 March 2025

10. Creditors	2025	2024
Amounts falling due within one year	€	€
Amounts owed to credit institutions	3,220	784
Trade creditors	121,131	106,278
Taxation	30,205	29,703
Directors' current accounts (Note 13)	3,834	327
Accruals	20,022	17,796
	<u>178,412</u>	<u>154,888</u>

11. Income Statement	Profit and loss account €	Capital redemption reserve €	Total €
At 1 April 2024	1,007,970	100	1,008,070
Profit/(loss) for the financial year	163,206	-	163,206
At 31 March 2025	<u>1,171,176</u>	<u>100</u>	<u>1,171,276</u>

## 12. Capital commitments

The company had no material capital commitments at the financial year-ended 31 March 2025.

13. Directors' remuneration and transactions	2025	2024
	€	€
Remuneration	125,400	136,323
Pension contributions	68,598	234,000
	<u>193,998</u>	<u>370,323</u>

The following amounts are repayable to the directors:

2025	2024
€	€
<u>3,834</u>	<u>327</u>

## 14. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

## 15. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 10 December 2025.